Literature DB >> 12860009

Flow cytometric analysis of aneuploidy and S-phase fraction in chronic myeloid leukemia patients: role in early detection of accelerated phase.

Anil K Tripathi1, Rupesh Chaturvedi, Rizwan Ahmad, Mohd Asim, Kamal K Sawlani, Manoj K Singh, Payal Tripathi, Babu L Tekwani.   

Abstract

We studied S-phase fraction (SPF) and aneuploidy in peripheral blood leucocytes of patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP, n=41), accelerated phase (CML-AP, n=6), and control subjects (n=12) with an aim to find out their role in early detection of accelerated phase. The SPF and aneuploidy were studied through flow-cytometry using LT-Mod. Fit software. Mean SPF value in CML-AP (9.28+/-3.46%) and in CML-CP (4.76+/-2.30%) were significantly higher than in normal controls (0.28+/-0.21%), (P<0.005, P<0.001). CML-CP patients having higher SPF (>7%) converted to accelerated phase within 18 months of follow-up while those with lower SPF (<7%) did not. Aneuploidy was present in 34.14% of CML-CP and all patients of CML-AP whereas no control subjects showed aneuploidy. Among CML-CP patients having SPF >7%, 86% developed aneuploidy during follow-up as compared to 18.50% of CML-CP with less than 7% SPF. We conclude that peripheral blood SPF and aneuploidy could be important parameters for prediction of evolution to accelerated phase in CML patients.

Entities:  

Mesh:

Year:  2003        PMID: 12860009     DOI: 10.1016/s0145-2126(03)00025-0

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Chromatin-bound PCNA as S-phase marker in mononuclear blood cells of patients with acute lymphoblastic leukaemia or multiple myeloma.

Authors:  F Zölzer; O Basu; P U Devi; S P Mohanty; C Streffer
Journal:  Cell Prolif       Date:  2010-12       Impact factor: 6.831

2.  Diagnostic and prognostic values of S-phase fraction and aneuploidy in patients with bone marrow aplasia.

Authors:  Payal Tripathi; Anil Kumar Tripathi; Ashutosh Kumar; Rizwan Ahmad; Anil Kumar Balapure; Achchhe Lal Vishwakerma
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.